As per GOI’s circular on price-capping of stents by NPPA(National Pharmaceutical Pricing Authority), new prices of coronary stents have been implemented effective 14th February, 2017. For details on stent pricing, across our hospitals. CLICK HERE

Media Room

Fortis Q3Fy16 Consolidated India Revenues At Rs 1029 Cr

Date : February 04, 2016

Fortis Healthcare Ltd. (Fortis), India’s leading healthcare delivery Company, today, announced its consolidated results for the quarter ended December 31, 2015 (Q3FY16).

The Board of Directors at its meeting today also approved the acquisition of a 51% economic interest in Fortis Hospotel Limited (FHTL), a subsidiary of the Religare Health Trust comprising the Fortis Shalimar Bagh, New Delhi and the Fortis Memorial Research Institute (FMRI), Gurgaon Clinical establishments. A separate Press Release outlining the details and key highlights of the aforesaid transaction is being released along with this Press Release.

India Business - Key Highlights for the Quarter (Q3FY16)

Consolidated India Business Revenues were at Rs 1,029 Cr versus Rs 971 Cr in the corresponding quarter, last year. Operating EBITDAC (EBITDA before net business trust costs) was at Rs 161 Cr, representing a 15.7% margin versus a 15.6% margin in the corresponding previous quarter.
Consolidated operating EBITDA (post net BT fees) was at Rs 48 Cr, +25% growth over Q3 FY15.
India hospital business revenues were at Rs 850 Cr as compared to Rs 792 Cr in the corresponding previous quarter, a growth of 7%. Operating EBITDAC was at Rs 122 representing a margin of 14.3%.

For more information, please contact:
Fortis Healthcare:
Priya Bendre - 77385 70894
priya.bendre@fortishealthcare.com

Read Complete Press Release on below link:

Download Pdf - English

PrintCopy TextGo Back